<DOC>
	<DOCNO>NCT00020371</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness BMS-247550 treating patient cancer respond previous therapy .</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Cancers That Have Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , dose-limiting toxic effect , recommend phase II dose BMS-247550 patient refractory neoplasm . II . Evaluate pharmacokinetics pharmacodynamics drug patient . III . Determine occurrence response patient treated drug . PROTOCOL OUTLINE : This dose-escalation study . Patients receive BMS-247550 IV 1 hour day 1-5 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos BMS-247550 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity ( DLT ) . Once MTD determine , additional patient accrue receive BMS-247550 recommend phase II dose . If neutropenia identify DLT , second dose escalation perform identify MTD BMS-247550 addition filgrastim ( G-CSF ) cohort . Patients receive fixed-dose G-CSF 72 hour final BMS-247550 dose , continue blood level return normal . PROJECTED ACCRUAL : A total 45 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically cytologically confirm neoplasm refractory standard therapy standard therapy exist No CNS malignancy Prior/Concurrent Therapy Biologic therapy : At least 4 month since prior myeloablative chemotherapy follow bone marrow stem cell rescue Chemotherapy : See Biologic therapy At least 4 week since prior chemotherapy ( 6 week prior nitrosoureas mitomycin ) Endocrine therapy : At least 2 week since prior hormonal therapy breast cancer At least 4 week since prior hormonal therapy prostate cancer Radiotherapy : At least 4 week since prior radiotherapy No prior craniospinal irradiation , total body irradiation , radiation half pelvis Surgery : Not specify Other : No concurrent investigational drug Patient Characteristics Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm3 Absolute granulocyte count least 1,500/mm3 Hepatic : SGOT/SGPT great 2.5 time normal Bilirubin great 1.5 time normal ( great 3 time normal evidence Gilbert 's disease ) Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study No nonmalignant systemic disease serious medical illness No active uncontrolled infection HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>bone marrow suppression</keyword>
	<keyword>cancer</keyword>
	<keyword>cancer-related problem/condition</keyword>
	<keyword>neutropenia</keyword>
	<keyword>solid tumor</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>